Company: ADPT
Filing Date: 2025-11-05
Form Type: 10-Q
Source: 0001193125-25-267061
Chunk: 1

Company: Adaptive Biotechnologies Corp
Filing Date: 2025-11-05
Form: 10-Q
Item: Item 1
Chunk 1
---
 current portion

     72,361

     79,148

     Deferred revenue, less current portion

     1,206

     27,256

     Revenue interest liability, net, less current portion

     129,409

     132,414

     Other long-term liabilities

     20

     20

     Total liabilities

     286,357

     336,891

     Commitments and contingencies (Note 9)

     Shareholders’ equity

     Preferred stock: $0.0001 par value, 10,000,000 shares authorized at September 30, 2025 and December 31, 2024; no shares issued and outstanding at September 30, 2025 and December 31, 2024

     —

     —

     Common stock: $0.0001 par value, 340,000,000 shares authorized at September 30, 2025 and December 31, 2024; 152,581,042 and 147,773,744 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively

     15

     14

     Additional paid-in capital

     1,553,953

     1,506,353

     Accumulated other comprehensive gain

     211

     166

     Accumulated deficit

     (1,349,744
     )

     (1,303,824
     )

     Total Adaptive Biotechnologies Corporation shareholders’ equity

     204,435

     202,709

     Noncontrolling interest

     (182
     )

     (224
     )

     Total shareholders’ equity

     204,253

     202,485

     Total liabilities and shareholders’ equity
      
     $
     490,610

     $
     539,376

The accompanying notes are an integral part of these condensed consolidated financial statements.